

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021

July 20, 2021

HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- <u>Kiniksa Pharmaceuticals, Ltd.</u> (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. Eastern Time to report its second quarter 2021 financial results and recent corporate and portfolio activity.

A live webcast will be accessible through the Investors & Media section of the company's website at <u>www.kiniksa.com</u>. A replay of the webcast will be available on Kiniksa's website for 14 days following the conference. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 1485623.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of assets, ARCALYST [®] (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST[®] is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!™

Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com



Source: Kiniksa Pharmaceuticals, Ltd.